High-risk oncogenic HPV genotype infection associates with increased immune activation and T cell exhaustion in ART-suppressed HIV-1-infected women

OncoImmunology

Volumn 5, Issue 5, 2016, Pages

  Papasavvas, Emmanouil ^a   Surrey, Lea F ^b   Glencross, Deborah K ^c,d   Azzoni, Livio ^a   Joseph, Jocelin ^a   Omar, Tanvier ^c,d   Feldman, Michael D ^b   Williamson, Anna Lise ^d,e   Siminya, Maureen ^c,f   Swarts, Avril ^c,f   Yin, Xiangfan ^a   Liu, Qin ^a   Firnhaber, Cynthia ^c,f   Montaner, Luis J ^a  

^a WISTAR INSTITUTE   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f RIGHT TO CARE   (South Africa)

Author keywords

Activation; ART; Exhaustion; HIV; HPV

Indexed keywords

ALLOPHYCOCYANIN; PROGRAMMED DEATH 1 LIGAND 1;

ARTICLE; CD4 LYMPHOCYTE COUNT; CELL DENSITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PUNCH BIOPSY; RISK FACTOR; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA;

EID: 84965051430     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1128612     Document Type: Article

References (65)

1. F.X.Bosch, M.M.Manos, N.Munoz, M.Sherman, A.M.Jansen, J.Peto, M.H.Schiffman, V.Moreno, R.Kurman, K.V.Shah. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87:796–802; PMID:7791229; http://dx.doi.org/10.1093/jnci/87.11.796.
2. G.Y.Ho, R.Bierman, L.Beardsley, C.J.Chang, R.D.Burk. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338:423–8; PMID:9459645; http://dx.doi.org/10.1056/NEJM199802123380703.
3. M.Maiman, R.G.Fruchter, M.Clark, C.D.Arrastia, R.Matthews, E.J.Gates. Cervical cancer as an AIDS-defining illness. Obstet Gynecol 1997; 89:76–80; PMID:8990442; http://dx.doi.org/10.1016/S0029-7844(96)00378-X.
4. B.Nonnenmacher, N.L.Hubbert, R.Kirnbauer, K.V.Shah, N.Munoz, F.X.Bosch, S.de Sanjosé, R.Viscidi, D.R.Lowy, J.T.Schiller. Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain. J Infect Dis 1995; 172:19–24; PMID:7797910; http://dx.doi.org/10.1093/infdis/172.1.19.
5. J.M.Palefsky, E.A.Holly, M.L.Ralston, N.Jay, J.M.Berry, T.M.Darragh. High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. Aids 1998; 12:495–503; PMID:9543448; http://dx.doi.org/10.1097/00002030-199805000-00011.
6. A.Petter, K.Heim, M.Guger, A.Ciresa-Ko Nig, N.Christensen, M.Sarcletti, U.Wieland, H.Pfister, R.Zangerle, R.Höpfl. Specific serum IgG, IgM and IgA antibodies to human papillomavirus types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive women. J Gen Virol 2000; 81:701–8; PMID:10675407; http://dx.doi.org/10.1099/0022-1317-81-3-701.
7. J.C.Steele, C.H.Mann, S.Rookes, T.Rollason, D.Murphy, M.G.Freeth, P.H.Gallimore, S.Roberts. T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia. Br J Cancer 2005; 93:248–59; PMID:15986031; http://dx.doi.org/10.1038/sj.bjc.6602679.
8. J.M.Walboomers, M.V.Jacobs, M.M.Manos, F.X.Bosch, J.A.Kummer, K.V.Shah, P.J.Snijders, J.Peto, C.J.Meijer, N.Muñoz. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12–9; PMID:10451482; http://dx.doi.org/10.1002/(SICI)1096-9896(199909)189:1%3c12::AID-PATH431%3e3.0.CO;2-F.
9. D.Bzhalava, C.Eklund, J.Dillner. International standardization and classification of human papillomavirus types. Virology 2015; 476:341–4; PMID:25577151; http://dx.doi.org/10.1016/j.virol.2014.12.028.
10. S.de Sanjose, W.G.Quint, L.Alemany, D.T.Geraets, J.E.Klaustermeier, B.Lloveras, S.Tous, A.Felix, L.E.Bravo, H.R.Shin Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11:1048–56; PMID:20952254; http://dx.doi.org/10.1016/S1470-2045(10)70230-8.
11. N.Munoz, F.X.Bosch, S.de Sanjose, R.Herrero, X.Castellsague, K.V.Shah, P.J.Snijders, C.J.Meijer, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518–27; PMID:12571259; http://dx.doi.org/10.1056/NEJMoa021641.
12. M.H.Schiffman. Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst 1992; 84:394–8; PMID:1311392; http://dx.doi.org/10.1093/jnci/84.6.394.
13. J.S.Smith, L.Lindsay, B.Hoots, J.Keys, S.Franceschi, R.Winer, G.M.Clifford. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121:621–32; PMID:17405118; http://dx.doi.org/10.1002/ijc.22527.
14. A.S.Kadish, P.Timmins, Y.Wang, G.Y.Ho, R.D.Burk, J.Ketz, W.He, S.L.Romney, A.Johnson, R.Angeletti Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol Biomarkers Prev 2002; 11:483–8; PMID:12010863.
15. J.Palefsky. Human papillomavirus-related tumors in HIV. Curr Opin Oncol 2006; 18:463–8; PMID:16894294; http://dx.doi.org/10.1097/01.cco.0000239885.13537.36.
16. T.C.Wright, Jr, J.T.Cox, L.S.Massad, L.B.Twiggs, E.J.Wilkinson. 2001 Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalities. J Low Genit Tract Dis 2002; 6:127–43; PMID:17051012; http://dx.doi.org/10.1097/00128360-200204000-00012.
17. M.Connors, J.A.Kovacs, S.Krevat, J.C.Gea-Banacloche, M.C.Sneller, M.Flanigan, J.A.Metcalf, R.E.Walker, J.Falloon, M.Baseler HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997; 3:533–40; PMID:9142122; http://dx.doi.org/10.1038/nm0597-533.
18. M.Grant, I.Pardoe, M.Whaley, J.S.Montaner, P.R.Harrigan. The T cell receptor V β repertoire shows little change during treatment interruption-related viral rebound in chronic HIV infection. Aids 2002; 16:287–90; PMID:11807314; http://dx.doi.org/10.1097/00002030-200201250-00019.
19. I.Heard, V.Schmitz, D.Costagliola, G.Orth, M.D.Kazatchkine. Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. Aids 1998; 12:1459–64; PMID:9727566; http://dx.doi.org/10.1097/00002030-199812000-00007.
20. I.Heard, J.M.Tassie, M.D.Kazatchkine, G.Orth. Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. Aids 2002; 16:1799–802; PMID:12218392; http://dx.doi.org/10.1097/00002030-200209060-00013.
21. H.Minkoff, L.Ahdieh, L.S.Massad, K.Anastos, D.H.Watts, S.Melnick, L.Muderspach, R.Burk, J.Palefsky. The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. Aids 2001; 15:2157–64; PMID:11684935; http://dx.doi.org/10.1097/00002030-200111090-00011.
22. F.B.Lillo, D.Ferrari, F.Veglia, M.Origoni, M.A.Grasso, S.Lodini, E.Mastrorilli, G.Taccagni, A.Lazzarin, C.Uberti-Foppa. Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. J Infect Dis 2001; 184:547–51; PMID:11494160; http://dx.doi.org/10.1086/322856.
23. P.Schuman, S.E.Ohmit, R.S.Klein, A.Duerr, S.Cu-Uvin, D.J.Jamieson, J.Anderson, K.V.Shah; HIV Epidemiology Research Study (HERS) Group. Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 2003; 188:128–36; PMID:12825181; http://dx.doi.org/10.1086/375783.
24. L.Ahdieh-Grant, R.Li, A.M.Levine, L.S.Massad, H.D.Strickler, H.Minkoff, M.Moxley, J.Palefsky, H.Sacks, R.D.Burk Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst 2004; 96:1070–6; PMID:15265968; http://dx.doi.org/10.1093/jnci/djh192.
25. L.J.Conley, T.V.Ellerbrock, T.J.Bush, M.A.Chiasson, D.Sawo, T.C.Wright. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet 2002; 359:108–13; PMID:11809252; http://dx.doi.org/10.1016/S0140-6736(02)07368-3.
26. J.M.Palefsky, E.A.Holly, M.L.Ralston, M.Da Costa, H.Bonner, N.Jay, J.M.Berry, T.M.Darragh. Effect of highly active antiretroviral therapy on the natural history of anal squamous intraepithelial lesions and anal human papillomavirus infection. J Acquir Immune Defic Syndr 2001; 28:422–8; PMID:11744829; http://dx.doi.org/10.1097/00042560-200112150-00003.
27. M.A.French, M.S.King, J.M.Tschampa, B.A.da Silva, A.L.Landay. Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. J Infect Dis 2009; 200:1212–5; PMID:19728788; http://dx.doi.org/10.1086/605890.
28. M.M.Lederman, L.Calabrese, N.T.Funderburg, B.Clagett, K.Medvik, H.Bonilla, B.Gripshover, R.A.Salata, A.Taege, M.Lisgaris Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis 2011; 204:1217–26; PMID:21917895; http://dx.doi.org/10.1093/infdis/jir507.
29. H.Valdez, E.Connick, K.Y.Smith, M.M.Lederman, R.J.Bosch, R.S.Kim, M.St Clair, D.R.Kuritzkes, H.Kessler, L.Fox Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002; 16:1859–66; PMID:12351945; http://dx.doi.org/10.1097/00002030-200209270-00002.
30. P.W.Hunt, H.L.Cao, C.Muzoora, I.Ssewanyana, J.Bennett, N.Emenyonu, A.Kembabazi, T.B.Neilands, D.R.Bangsberg, S.G.Deeks Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS 2011; 25:2123–31; PMID:21881481; http://dx.doi.org/10.1097/QAD.0b013e32834c4ac1.
31. J.Chehimi, D.E.Campbell, L.Azzoni, D.Bacheller, E.Papasavvas, G.Jerandi, K.Mounzer, J.Kostman, G.Trinchieri, L.J.Montaner. Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J Immunol 2002; 168:4796–801; PMID:11971031; http://dx.doi.org/10.4049/jimmunol.168.9.4796.
32. N.Sachdeva, V.Asthana, T.H.Brewer, D.Garcia, D.Asthana. Impaired restoration of plasmacytoid dendritic cells in HIV-1-infected patients with poor CD4 T cell reconstitution is associated with decrease in capacity to produce IFN-α but not proinflammatory cytokines. J Immunol 2008; 181:2887–97; PMID:18684980; http://dx.doi.org/10.4049/jimmunol.181.4.2887.
33. A.C.Hearps, A.Maisa, W.J.Cheng, T.A.Angelovich, G.F.Lichtfuss, C.S.Palmer, A.L.Landay, A.Jaworowski, S.M.Crowe. HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy. AIDS 2012; 26:843–53; PMID:22313961; http://dx.doi.org/10.1097/QAD.0b013e328351f756.
34. S.Fernandez, P.Price, E.J.McKinnon, R.C.Nolan, M.A.French. Low CD4+ T-cell counts in HIV patients receiving effective antiretroviral therapy are associated with CD4+ T-cell activation and senescence but not with lower effector memory T-cell function. Clin Immunol 2006; 120:163–70; PMID:16765088; http://dx.doi.org/10.1016/j.clim.2006.04.570.
35. M.Goicoechea, D.M.Smith, L.Liu, S.May, A.R.Tenorio, C.C.Ignacio, A.Landay, R.Haubrich. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis 2006; 194:29–37; PMID:16741879; http://dx.doi.org/10.1086/504718.
36. P.W.Hunt, J.N.Martin, E.Sinclair, B.Bredt, E.Hagos, H.Lampiris, S.G.Deeks. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187:1534–43; PMID:12721933; http://dx.doi.org/10.1086/374786.
37. D.Nakanjako, I.Ssewanyana, H.Mayanja-Kizza, A.Kiragga, R.Colebunders, Y.C.Manabe, R.Nabatanzi, M.R.Kamya, H.Cao. High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort. BMC Infect Dis 2011; 11:43; PMID:21299909; http://dx.doi.org/10.1186/1471-2334-11-43.
38. P.W.Hunt, J.N.Martin, E.Sinclair, L.Epling, J.Teague, M.A.Jacobson, R.P.Tracy, L.Corey, S.G.Deeks. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis 2011; 203:1474–83; PMID:21502083; http://dx.doi.org/10.1093/infdis/jir060.
39. S.Kottilil, M.Y.Yan, K.N.Reitano, X.Zhang, R.Lempicki, G.Roby, M.Daucher, J.Yang, K.J.Cortez, M.Ghany Human immunodeficiency virus and hepatitis C infections induce distinct immunologic imprints in peripheral mononuclear cells. Hepatology 2009; 50:34–45; PMID:19551908; http://dx.doi.org/10.1002/hep.23055.
40. H.Rempel, B.Sun, C.Calosing, L.Abadjian, A.Monto, L.Pulliam. Monocyte activation in HIV/HCV coinfection correlates with cognitive impairment. PLoS One 2013; 8:e55776; PMID:23437063; http://dx.doi.org/10.1371/journal.pone.0055776.
41. A.Kovacs, L.Al-Harthi, S.Christensen, W.Mack, M.Cohen, A.Landay. CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus. J Infect Dis 2008; 197:1402–7; PMID:18444798; http://dx.doi.org/10.1086/587696.
42. V.D.Gonzalez, K.Falconer, K.G.Blom, O.Reichard, B.Morn, A.L.Laursen, N.Weis, A.Alaeus, J.K.Sandberg. High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by α interferon and ribavirin treatment. J Virol 2009; 83:11407–11; PMID:19710147; http://dx.doi.org/10.1128/JVI.01211-09.
43. J.Cuzick. A Wilcoxon-type test for trend. Stat Med 1985; 4:87–90; PMID:3992076; http://dx.doi.org/10.1002/sim.4780040112.
44. A.S.Bergot, N.Ford, G.R.Leggatt, J.W.Wells, I.H.Frazer, M.A.Grimbaldeston. HPV16-E7 expression in squamous epithelium creates a local immune suppressive environment via CCL2- and CCL5- mediated recruitment of mast cells. PLoS Pathog 2014; 10:e1004466; PMID:25340820; http://dx.doi.org/10.1371/journal.ppat.1004466.
45. A.Kobayashi, R.M.Greenblatt, K.Anastos, H.Minkoff, L.S.Massad, M.Young, A.M.Levine, T.M.Darragh, V.Weinberg, K.K.Smith-McCune. Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res 2004; 64:6766–74; PMID:15374995; http://dx.doi.org/10.1158/0008-5472.CAN-04-1091.
46. M.Mhatre, T.McAndrew, C.Carpenter, R.D.Burk, M.H.Einstein, B.C.Herold. Cervical intraepithelial neoplasia is associated with genital tract mucosal inflammation. Sex Transm Dis 2012; 39:591–7; PMID:22801340; http://dx.doi.org/10.1097/OLQ.0b013e318255aeef.
47. T.T.Prata, C.M.Bonin, A.M.Ferreira, C.T.Padovani, C.E.Fernandes, A.P.Machado, I.A.Tozetti. Local immunosuppression induced by high viral load of human papillomavirus: characterization of cellular phenotypes producing interleukin-10 in cervical neoplastic lesions. Immunology 2015; 146:113–21; PMID:26059395; http://dx.doi.org/10.1111/imm.12487.
48. Y.E.Chang, L.A.Laimins. Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J Virol 2000; 74:4174–82; PMID:10756030; http://dx.doi.org/10.1128/JVI.74.9.4174-4182.2000.
49. M.Nees, J.M.Geoghegan, T.Hyman, S.Frank, L.Miller, C.D.Woodworth. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J Virol 2001; 75:4283–96; PMID:11287578; http://dx.doi.org/10.1128/JVI.75.9.4283-4296.2001.
50. P.Barnard, N.A.McMillan. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-α. Virology 1999; 259:305–13; PMID:10388655; http://dx.doi.org/10.1006/viro.1999.9771.
51. L.V.Ronco, A.Y.Karpova, M.Vidal, P.M.Howley. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 1998; 12:2061–72; PMID:9649509; http://dx.doi.org/10.1101/gad.12.13.2061.
52. M.Stanley. Immune responses to human papillomavirus. Vaccine 2006; 24 Suppl 1:S16–22; PMID:16219398; http://dx.doi.org/10.1016/j.vaccine.2005.09.002.
53. J.Malejczyk, M.Malejczyk, S.Majewski, G.Orth, S.Jablonska. NK-cell activity in patients with HPV16-associated anogenital tumors: defective recognition of HPV16-harboring keratinocytes and restricted unresponsiveness to immunostimulatory cytokines. Int J Cancer 1993; 54:917–21; PMID:8392981; http://dx.doi.org/10.1002/ijc.2910540608.
54. C.Mougin, L.Mo, V.Dalstein. [Natural history of papillomavirus infections]. Rev Prat 2006; 56:1883–9; PMID:17243385.
55. J.Visser, H.W.Nijman, B.N.Hoogenboom, P.Jager, D.van Baarle, E.Schuuring, W.Abdulahad, F.Miedema, A.G.van der Zee, T.Daemen. Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia. Clin Exp Immunol 2007; 150:199–209; PMID:17937675; http://dx.doi.org/10.1111/j.1365-2249.2007.03468.x.
56. Y.Agata, A.Kawasaki, H.Nishimura, Y.Ishida, T.Tsubata, H.Yagita, T.Honjo. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996; 8:765–72; PMID:8671665; http://dx.doi.org/10.1093/intimm/8.5.765.
57. L.J.Hatam, J.A.Devoti, D.W.Rosenthal, F.Lam, A.L.Abramson, B.M.Steinberg, V.R.Bonagura. Immune suppression in premalignant respiratory papillomas: enriched functional CD4+Foxp3+ regulatory T cells and PD-1/PD-L1/L2 expression. Clin Cancer Res 2012; 18:1925–35; PMID:22322668; http://dx.doi.org/10.1158/1078-0432.CCR-11-2941.
58. A.L.Kinter, E.J.Godbout, J.P.McNally, I.Sereti, G.A.Roby, M.A.O'Shea, A.S.Fauci. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol 2008; 181:6738–46; PMID:18981091; http://dx.doi.org/10.4049/jimmunol.181.10.6738.
59. F.Hirano, K.Kaneko, H.Tamura, H.Dong, S.Wang, M.Ichikawa, C.Rietz, D.B.Flies, J.S.Lau, G.Zhu Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005; 65:1089–96; PMID:15705911.
60. F.S.Hodi, M.C.Mihm, R.J.Soiffer, F.G.Haluska, M.Butler, M.V.Seiden, T.Davis, R.Henry-Spires, S.MacRae, A.Willman Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003; 100:4712–7; PMID:12682289; http://dx.doi.org/10.1073/pnas.0830997100.
61. G.Q.Phan, J.C.Yang, R.M.Sherry, P.Hwu, S.L.Topalian, D.J.Schwartzentruber, N.P.Restifo, L.R.Haworth, C.A.Seipp, L.J.Freezer Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003; 100:8372–7; PMID:12826605; http://dx.doi.org/10.1073/pnas.1533209100.
62. T.H.Su, T.Y.Chang, Y.J.Lee, C.K.Chen, H.F.Liu, C.C.Chu, M.Lin, P.T.Wang, W.C.Huang, T.C.Chen CTLA-4 gene and susceptibility to human papillomavirus-16-associated cervical squamous cell carcinoma in Taiwanese women. Carcinogenesis 2007; 28:1237–40; PMID:17341658; http://dx.doi.org/10.1093/carcin/bgm043.
63. W.Yang, Y.Song, Y.L.Lu, J.Z.Sun, H.W.Wang. Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia. Immunology 2013; 139:513–22; PMID:23521696; http://dx.doi.org/10.1111/imm.12101.
64. C.Firnhaber, H.Van Le, A.Pettifor, D.Schulze, P.Michelow, I.M.Sanne, D.A.Lewis, A.L.Williamson, B.Allan, S.Williams Association between cervical dysplasia and human papillomavirus in HIV seropositive women from Johannesburg South Africa. Cancer Causes Control 2010; 21:433–43; PMID:19949850; http://dx.doi.org/10.1007/s10552-009-9475-z.
65. E.Papasavvas, G.M.Ortiz, R.Gross, J.Sun, E.C.Moore, J.J.Heymann, M.Moonis, J.K.Sandberg, L.A.Drohan, B.Gallagher Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. J Infect Dis 2000; 182:766–75; PMID:10950770; http://dx.doi.org/10.1086/315748.